Regentis Biomaterials Ltd (RGNT) — Titan Protect Analysis

RGNT

Regentis Biomaterials Ltd

Healthcare · ·

$1.32

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+658% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Regentis Biomaterials Ltd

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is

https://www.regentis.co.il

Country: Israel Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-3.188

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.4755

No positive edge detected — the data suggests staying out

Calmar Ratio

-1.203

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-94.9%

Historical annualised return based on price data

Max Drawdown

-78.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$8.35

84% below the year high

52W Low

$1.54

-14% above the year low

Avg Volume

13,753

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-24.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

25.23

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$3M

Positive — the business generates more cash than it spends

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-13,692,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$10.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go